Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
Holding ESPR?
Track your performance easily
ESPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.70 - $3.40
Previous Close$1.77
Volume3.16M
Average Volume (3M)7.10M
Market Cap
$347.32M
Enterprise Value$427.15M
Total Cash (Recent Filing)$189.30M
Total Debt (Recent Filing)$269.13M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 05, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding196,224,695
10 Day Avg. Volume4,918,238
30 Day Avg. Volume7,101,749
Standard Deviation0.27
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.97
Price to Sales (P/S)1.21
Price to Cash Flow (P/CF)-11.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit5.85
Enterprise Value/Ebitda-8.05
Forecast
1Y Price Target
$9.67Price Target Upside446.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Esperion News
PremiumCompany Announcements
Esperion Announces CMO Transition and Continued Advisory RoleBulls Say, Bears Say
Bulls Say
Financial PerformanceRevenues were ahead of consensus estimates, driven by recognition of collaboration from the settlement agreement with European partner Daiichi Sankyo Europe.
Market ExpansionExpanded labels are beginning to drive accelerating demand growth.
Strategic InitiativesThe company is leveraging the expanded labels through broad commercial initiatives, including a larger sales force, digital marketing campaigns, and meaningfully improved payor access.
Bears Say
Competitive PressureMerck’s oral PCSK9i and New Amsterdam’s obicetrapib boast greater LDL-C lowering abilities, prompting experts to believe both will be favored if available.
Market ChallengesThe primary prevention market is underdeveloped, and most of the upside is likely to be driven by secondary prevention, where there are still challenges competing against more effective agents.
Sales PerformanceNexletol/Nexlizet's 2Q24 sales of $28.3MM came in below the Street's $32.8MM as the growth inflection is taking more time than expected to materialize.
---
Ownership Overview
6.96% Insiders
13.59% Mutual Funds
41.35% Other Institutional Investors
38.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.70 and its highest was $3.40 in the past 12 months.
What is Esperion’s market cap?
Currently, no data Available
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Nov 05, 2024 which is in 73 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Aug 12, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.172 by -$0.158.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -$0.17.
How many shares outstanding does Esperion have?
Esperion has 196,224,700 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.172. Following the earnings report the stock price went down -8.911%.
Which hedge fund is a major shareholder of Esperion?
Among the largest hedge funds holding Esperion’s share is Woodline Partners LP. It holds Esperion’s shares valued at 11M.
---
Esperion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.67 (446.33% Upside)
$9.67 (446.33% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
50.16%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
ESPR Company Deck
---
ESPR Earnings Call
Q2 2024
0:00 / 0:00
---
ESPR Stock 12 Month Forecast
Average Price Target
$9.67
▲(446.33% Upside)
Technical Analysis
Best Analysts Covering ESPR
1 Year
1 Year Success Rate
9/26 ratings generated profit
1 Year Average Return
+25.22%
reiterated a buy rating 5 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 34.62% of your transactions generating a profit, with an average return of +25.22% per trade.
---